Pyrotinib Plus Capecitabine For Her2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: A Pooled Analysis Of Three Randomized Controlled Trials.

Zefei Jiang,Binghe Xu,Min Yan,Quchang Ouyang,Xi-Chun Hu, Wei Li,Ji Feng Feng,Qingyuan Zhang,Zhongsheng Tong,Ping Yan,Xiaoyu Zhu,Shangyi Rong,Jianjun Zou

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览46

暂无评分

摘要

1048Background: Trastuzumab is the most widely used anti-HER2 agent in patients (pts) with HER2-positive breast cancer, both in (neo)adjuvant and metastatic settings; however, drug resistance is in...

查看译文

关键词

Trastuzumab,Breast Cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要